title: Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration.
abstract: Neurodegeneration in Alzheimer's disease (AD) correlates with dysfunction of signaling mediated by Galphaq/11. Nondissociable angiotensin II AT2 receptor oligomers are linked to the impaired Galphaq/11-stimulated signaling of AD patients and transgenic mice with AD-like symptoms. To further analyze the role of AT2 receptor oligomers, we induced the formation of AT2 oligomers in an in vitro cell system. Similarly as in vivo, sequential oxidative and transglutaminase-dependent cross-linking steps triggered the formation of AT2 oligomers in vitro. Elevated reactive oxygen species mediated oxidative cross-linking of AT2 monomers to dimers involving tyrosine residues located at putative interreceptor contact sites of the cytoplasmic loop connecting transmembrane helices III/IV. Cross-linked AT2 dimers were subsequently a substrate of activated transglutaminase-2, which targeted the carboxyl terminus of AT2 dimers, as assessed by truncated and chimeric AT2 receptors, respectively. AT2 oligomers acted as dominant negative receptors in vitro by mediating Galphaq/11 protein sequestration and Galphaq/11 protein arrest. The formation of AT2 oligomers and G-protein dysfunction could be suppressed in vitro and in vivo by an AT2 receptor mutant. Inhibition of AT2 oligomerization upon stereotactic expression of the AT2 receptor mutant revealed that Galphaq/11-sequestering AT2 oligomers enhanced the development of neurodegenerative symptoms in the hippocampus of transgenic mice with AD-like pathology. Thus, AT2 oligomers inducing Galphaq/11 arrest are causally involved in inducing symptoms of neurodegeneration.
authors.affiliation: Heinrich-Pette-Institute, Martinistrasse 52, D-20251 Hamburg, Germany.
authors.forename: Said
authors.initials: S
authors.lastname: AbdAlla
authors.forename: Heinz
authors.initials: H
authors.lastname: Lother
authors.forename: Ahmed
authors.initials: A
authors.lastname: el Missiry
authors.forename: Pavel
authors.initials: P
authors.lastname: Sergeev
authors.forename: Andreas
authors.initials: A
authors.lastname: Langer
authors.forename: Yasser
authors.initials: Y
authors.lastname: el Faramawy
authors.forename: Ursula
authors.initials: U
authors.lastname: Quitterer
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D002460:Cell Line; D019281:Dimerization; D004195:Disease Models, Animal; D043802:GTP-Binding Protein alpha Subunits, Gq-G11 / Q000235:genetics / Q000378:metabolism*; D005799:Genes, Dominant; D006624:Hippocampus / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D010084:Oxidation-Reduction; D020836:Protein Structure, Quaternary / Q000235:genetics; D017433:Protein Structure, Secondary / Q000235:genetics; D044139:Receptor, Angiotensin, Type 2 / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000235:genetics
chemical_list: D044139:Receptor, Angiotensin, Type 2; D043802:GTP-Binding Protein alpha Subunits, Gq-G11